Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data with Initial Clinical Trial Results at AACR 2026

on

Verismo Therapeutics will present initial Phase 1 clinical data from its STAR-101 trial assessing SynKIR-110 in mesothelin-expressing solid tumors in an oral late-breaking presentation at AACR 20263

SynKIR-110 and SynKIR-310 are the first multi-chain KIR-CAR-based immuno-oncology therapies in human trials3

SynKIR-110 is being investigated for patients with advanced ovarian cancer, mesothelioma, or cholangiocarcinoma in the Phase 1 STAR-101 clinical trial3

SynKIR-310 preclinical and initial Phase 1 data from the CELESTIAL-301 trial assessing the therapy in B cell Non-Hodgkin Lymphoma will be presented in a poster presentation3

The KIR-CAR platform uses NK cell-derived KIR and DAP12 split-signaling to enable sustained chimeric receptor expression with improved long-term CAR T cell function and decreased T cell exhaustion3

Verismo's multi-chain KIR-CAR technology advances beyond current single-chain CAR T therapies which are limited by always-on tonic signaling and T cell exhaustion3

SynKIR-310 preclinical data showed faster and deeper tumor control with reduced cytokine levels compared to conventional CD19-targeting CAR T therapies1

Sources:

1. https://www.prnewswire.com/news-releases/verismo-therapeutics-shares-positive-preclinical-data-at-ash-2025-comparing-synkir-310-with-conventional-car-t-302636058.html

3. https://www.morningstar.com/news/pr-newswire/20260317ph12866/verismo-therapeutics-to-present-novel-multi-chain-kir-car-data-including-initial-clinical-trial-results-for-lead-immuno-oncology-candidates-synkir-110-and-synkir-310-at-aacr-annual-meeting-2026